We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Loss of p53 Promotes Survival of Cancer Stem Cells

By LabMedica International staff writers
Posted on 26 Oct 2017
Cancer researchers have found that the cellular cleansing process known as mitophagy is linked to the development and progression of liver cancer.

Mitophagy is the selective degradation of mitochondria by autophagy. More...
It often occurs to defective mitochondria following damage or stress. In addition to the selective removal of damaged mitochondria, mitophagy is also required to adjust mitochondrial numbers to changing cellular metabolic needs, for steady-state mitochondrial turnover, and during certain cellular developmental stages, such as during cellular differentiation of red blood cells.

Investigators at the University of Southern California (Los Angeles, USA) reported in the October 12, 2017, online edition of the journal Molecular Cell that mitophagy promoted the maintenance of hepatic cancer stem cells (CSCs) through the loss of the tumor suppressor protein p53, which was closely associated with the mitochondria.

When mitophagy was inhibited, the p53 protein on mitochondria was phosphorylated at serine-392 by the enzyme PINK1, a kinase associated with mitophagy. The phosphorylated p53 was then translocated into the nucleus, where it bound to the NANOG promoter. This binding prevented the OCT4 and SOX2 transcription factors from activating the expression of NANOG, a transcription factor critical for maintaining the stem cell properties and the self-renewal ability of CSCs, resulting in the reduction of hepatic CSC populations.

"Liver cancer is difficult to treat, and most patients who are diagnosed with it will die within a five-year period," said senior author Dr. Jing-Hsiung James Ou, professor of molecular microbiology and immunology at the University of Southern California. "My team has identified how liver cancer stem cells are maintained. Without these "seeds of cancer," liver tumors would shrink and eventually disappear. Now that we understand the molecular process, we will be able to target this pathway to stop the production of cancer stem cells. If cancer stem cells are gone, cancer is gone."

Related Links:
University of Southern California


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Urinalysis Solution
UN-9000
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.